Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 19/20 | 0.82 |
| ▸ | ERBB2 | P04626 | 15/20 | 0.82 |
| ▸ | MEN1 | O00255 | 1/20 | 0.71 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.71 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.71 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.71 |
| ▸ | PIK3C2G | O75747 | 1/20 | 0.71 |
| ▸ | STK10 | O94804 | 1/20 | 0.71 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.71 |
| ▸ | ABL1 | P00519 | 1/20 | 0.71 |
| ▸ | INSR | P06213 | 1/20 | 0.71 |
| ▸ | RET | P07949 | 1/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.71 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.71 |
| ▸ | SRC | P12931 | 1/20 | 0.71 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.71 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.71 |
| ▸ | CDK2 | P24941 | 1/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.71 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12200053 | 0.90 | EGFR (0.82) | EGFRERBB2MEN1PIK3C2BMAP2K7 | |
| SCHEMBL4004635 | 0.90 | EGFR (1.00) | EGFRERBB2MEN1PIK3C2BMAP2K7 | |
| SCHEMBL4009342 | 0.90 | EGFR (1.00) | EGFRERBB2MEN1PIK3C2BMAP2K7 | |
| SCHEMBL4005755 | 0.89 | EGFR (0.93) | EGFRERBB2MEN1PIK3C2BMAP2K7 | |
| SCHEMBL28350419 | 0.89 | EGFR (0.85) | EGFRERBB2MEN1PIK3C2BMAP2K7 | |
| SCHEMBL15766036 | 0.88 | EGFR (0.82) | EGFRERBB2MEN1PIK3C2BMAP2K7 | |
| SCHEMBL19627088 | 0.87 | EGFR (0.85) | EGFRERBB2MEN1PIK3C2BMAP2K7 | |
| SCHEMBL26358566 | 0.87 | EGFR (0.85) | EGFRERBB2MEN1PIK3C2BMAP2K7 | |
| SCHEMBL16995611 | 0.87 | EGFR (0.85) | EGFRERBB2MEN1PIK3C2BMAP2K7 | |
| Gw616030X SCHEMBL30467455 | 0.87 | EGFR (1.00) | EGFRERBB2MEN1PIK3C2BMAP2K7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2740729-B1 | QUINAZOLINE DERIVATIVE, COMPOSITION HAVING THE DERIVATIVE, AND USE OF THE DERIVATIVE IN PREPARING MEDICAMENT | HANGZHOU MINSHENG INSTITUTES FOR PHARMA RES (CN) | 2020-11-25 | — | — | EP | claimed |
| US-9499530-B2 | Quinazoline derivative, composition having the derivative, and use of the derivative in preparing medicament | HANGZHOU MINSHENG INSTITUTES FOR PHARMA RESEARCH (CN) | 2016-11-22 | — | — | US | claimed |
| US-20150080392-A1 | QUINAZOLINE DERIVATIVE, COMPOSITION HAVING THE DERIVATIVE, AND USE OF THE DERIVATIVE IN PREPARING MEDICAMENT | HANGZHOU MINSHENG PHARMACEUTICAL CO. LTD (CN) | 2015-03-19 | — | — | US | claimed |
| EP-2740729-A1 | QUINAZOLINE DERIVATIVE, COMPOSITION HAVING THE DERIVATIVE, AND USE OF THE DERIVATIVE IN PREPARING MEDICAMENT | Hangzhou Minsheng Institutes for Pharma Research (CN) | 2014-06-11 | — | — | EP | claimed |
| EP-2740729-B1 | QUINAZOLINE DERIVATIVE, COMPOSITION HAVING THE DERIVATIVE, AND USE OF THE DERIVATIVE IN PREPARING MEDICAMENT | HANGZHOU MINSHENG INSTITUTES FOR PHARMA RES (CN) | 2020-11-25 | — | — | EP | disclosed |
| EP-2740729-A1 | QUINAZOLINE DERIVATIVE, COMPOSITION HAVING THE DERIVATIVE, AND USE OF THE DERIVATIVE IN PREPARING MEDICAMENT | Hangzhou Minsheng Institutes for Pharma Research (CN) | 2014-06-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150080392-A1 | QUINAZOLINE DERIVATIVE, COMPOSITION HAVING THE DERIVATIVE, AND USE OF THE DERIVATIVE IN PREPARING MEDICAMENT | LCK, ZAP70, FYN | EGFR 24/4885ERBB2 6/4885MEN1 2017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.